Watch STRO. Know when insiders buy.
One email the day a filing lands. Free.
STRO
SUTRO BIOPHARMA, INC.
15.85
−0.13 −0.84%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $262.7MP/E —DIV YIELD —FCF YIELD —REV TTM $45.7M −56.3%NET INCOME −$180.6MNET CASH $50.3M52W 7.30 – 40.91SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $9.8M | −84.6% | — | −$29.9M | −$38.5M | — | -2.33 | −$38.3M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | $14.5M | −16.5% | — | −$29.7M | −$38.5M | — | -2.94 | −$42.3M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | $11.6M | −21.4% | — | −$38M | −$46.8M | — | -20.78 | −$26.4M | — | — | Mar 23 |
| Q3 2025 · Sep 30 | $9.7M | +13.8% | — | −$48.5M | −$56.9M | — | -0.67 | −$38.2M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $63.7M | +148.0% | — | −$3.3M | −$11.5M | — | -1.35 | −$44.7M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | $17.4M | +33.8% | — | −$68.5M | −$76M | — | -9.08 | −$67.9M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | $14.8M | −87.0% | — | −$65.3M | −$72.4M | −333.2% | -27.33 | −$71.7M | — | — | Mar 23 |
| Q3 2024 · Sep 30 | $8.5M | −49.7% | — | −$67.9M | −$48.8M | — | -0.59 | −$64.5M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $25.7M | — | — | −$48.7M | −$48M | — | -0.59 | $9.5M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | $13M | — | — | −$56.6M | −$58.2M | — | -0.59 | −$64.7M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | $113.7M | — | — | $43.2M | $31.1M | — | 0.52 | $14.1M | — | — | Mar 13 |
| Q3 2023 · Sep 30 | $16.9M | — | — | −$44M | −$49.3M | — | -0.81 | −$33.5M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $102.5M | — | −$158.4M | −$191.1M | -186.5% | -22.49 | −$177.2M | — | — | — | — |
| FY2024 · to Dec 31 | $62M | — | −$238.5M | −$227.5M | -366.6% | -29.40 | −$191.5M | — | — | — | — |
| FY2023 · to Dec 31 | $153.7M | — | −$89.3M | −$106.8M | -69.5% | -1.78 | −$111.6M | — | — | — | — |
| FY2022 · to Dec 31 | $67.8M | — | −$128.9M | −$119.2M | -175.9% | -2.35 | $3.5M | — | — | — | — |
| FY2021 · to Dec 31 | $61.9M | — | −$98.5M | −$105.5M | -170.6% | -2.29 | −$81.7M | — | — | $7K | — |
| FY2020 · to Dec 31 | $42.7M | — | −$71.1M | −$32.1M | -75.2% | -0.99 | −$67.8M | — | — | — | — |
Every number comes from SUTRO BIOPHARMA, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.